共 50 条
- [21] EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%ANNALS OF ONCOLOGY, 2018, 29Sriuranpong, V.Altundag, O.Clingan, P.Rizvi, N.Frontera, O. ArenSezer, A.Paydas, S.Shavdia, M.Bondarenko, I.Gladkov, O.Lee, S.Li, S.Snodgrass, P.Rietschel, P.
- [22] Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulationJOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S70 - S71Baramidze, A.Gessner, C.Gogishvili, M.Sezer, A.Makharadze, T.Kilickap, S.Gumus, M.He, X.Gullo, G.Rietschel, P.Quek, R.
- [23] Flexibility in chemotherapy regimens in first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with cemiplimab in combination with chemotherapy: analysis from EMPOWER-Lung 3LUNG CANCER, 2025, 200Rosen, Jan-PaulMakharadze, TamtaGogishvili, MirandaMelkadze, TamarBaramidze, AnaZhu, CongMcintyre, Debra AgVenkateshan, SatishKim, EricMagnan, HeatherPouliot, Jean -Francois
- [24] Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer populationANNALS OF ONCOLOGY, 2019, 30Frost, N.Kollmeier, J.Pultermann, D.Tessmer, A.Schmittel, A.Schmidt, B.Grah, C.de Wit, M.Misch, D.Blum, T.Suttorp, N.Grohe, C.
- [25] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%ADVANCES IN THERAPY, 2021, 38 (08) : 4354 - 4365Wang, LitingPeng, YeZeng, XiaohuiPeng, LiubaoLi, SiniQin, ShuxiaWan, XiaominTan, Chongqing
- [26] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%Advances in Therapy, 2021, 38 : 4354 - 4365Liting WangYe PengXiaohui ZengLiubao PengSini LiShuxia QinXiaomin WanChongqing Tan
- [27] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2209 - 2221Cortellini, AlessioTiseo, MarcelloBanna, Giuseppe L.Cappuzzo, FedericoAerts, Joachim G. J., VBarbieri, FaustoGiusti, RaffaeleBria, EmilioCortinovis, DiegoGrossi, FrancescoMigliorino, Maria R.Galetta, DomenicoPassiglia, FrancescoSantini, DanieleBerardi, RossanaMorabito, AlessandroGenova, CarloMazzoni, FrancescaDi Noia, VincenzoSignorelli, DiegoTuzi, AlessandroGelibter, AlainMarchetti, PaoloMacerelli, MariannaRastelli, FrancescaChiari, RitaRocco, DaniloGori, StefaniaDe Tursi, MicheleMansueto, GiovanniZoratto, FedericaSantoni, MatteoTudini, MariannaRijavec, ErikaFiletti, MarcoCatino, AnnamariaPizzutilo, PamelaSala, LucaCitarella, FabrizioMarco, RussanoTorniai, MariangelaCantini, LucaTargato, GiadaSforza, VincenzoNigro, OlgaFerrara, Miriam G.D'Argento, EttoreButi, SebastianoBordi, PaolaAntonuzzo, Lorenzo
- [28] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%Cancer Immunology, Immunotherapy, 2020, 69 : 2209 - 2221Alessio CortelliniMarcello TiseoGiuseppe L. BannaFederico CappuzzoJoachim G. J. V. AertsFausto BarbieriRaffaele GiustiEmilio BriaDiego CortinovisFrancesco GrossiMaria R. MigliorinoDomenico GalettaFrancesco PassigliaDaniele SantiniRossana BerardiAlessandro MorabitoCarlo GenovaFrancesca MazzoniVincenzo Di NoiaDiego SignorelliAlessandro TuziAlain GelibterPaolo MarchettiMarianna MacerelliFrancesca RastelliRita ChiariDanilo RoccoStefania GoriMichele De TursiGiovanni MansuetoFederica ZorattoMatteo SantoniMarianna TudiniErika RijavecMarco FilettiAnnamaria CatinoPamela PizzutiloLuca SalaFabrizio CitarellaRussano MarcoMariangela TorniaiLuca CantiniGiada TargatoVincenzo SforzaOlga NigroMiriam G. FerraraEttore D’ArgentoSebastiano ButiPaola BordiLorenzo Antonuzzo
- [29] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trialLANCET ONCOLOGY, 2023, 24 (09): : 989 - 1001Ozguroglu, MustafaKilickap, SaadettinSezer, AhmetGumus, MahmutBondarenko, IgorGogishvili, MirandaNechaeva, MarinaSchenker, MichaelCicin, IrfanHo, Gwo FuangKulyaba, YaroslavZyuhal, KasimovaScheusan, Roxana-IoanaGarassino, Marina ChiaraHe, XuanyaoKaul, ManikaOkoye, EmmanuelLi, YuntongLi, SiyuPouliot, Jean-FrancoisSeebach, FrankLowy, IsraelGullo, GiuseppeRietschel, Petra
- [30] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more(EMPOWER-Lung 1):35-month follow-up from a multicentre,open-label,randomised,phase 3 trial肿瘤药学, 2023, 13 (04) : 384 - 384Mustafa ?zgürogluSaadettin KilickapAhmet SezerMahmut GümüsIgor BondarenkoMiranda GogishviliMarina NechaevaMichael SchenkerIrfan CicinGwo Fuang HoYaroslav KulyabaKasimova ZyuhalRoxana-loana ScheusanMarina Chiara GarassinoXuanyao HeManika KaulEmmanuel OkoyeYuntong LiSiyu LiJean-Francois PouliotFrank SeebachIsrael LowyGiuseppe GulloPetra Rietschel房超